Abstract
This article evaluates the toxicity and feasibility of gemcitabine/nab-paclitaxel/S-1 chemotherapy on a 21-day cycle in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma, reporting dose-limiting toxicity and maximum tolerated dose of S-1 in this regimen.